Why Guardant Health Inc is Considered a Game-Changer in Cancer Diagnosis
Cancer is one of the deadliest diseases known to man. It’s estimated that one in three people will develop cancer at some point in their lives. However, with advances in medical technology, cancer diagnosis and treatment have become more sophisticated. One such advancement is Guardant Health Inc, which is disrupting the cancer diagnosis market with its innovative approach.
What is Guardant Health Inc?
Guardant Health Inc is a company that specializes in non-invasive cancer diagnostics. It was founded in 2012 in Redwood City, California, and has since become a pioneer in its field. The company developed the first liquid biopsy for cancer detection. This technology utilizes blood samples to identify cancer early on, up to two years before traditional methods.
How does Guardant Health Inc Work?
The liquid biopsy uses next-generation sequencing technology to analyze fragments of DNA in the bloodstream. These fragments are called circulating tumor DNA (ctDNA). The ctDNA is released when cancer cells die and break down. The Guardant Health Inc test can detect ctDNA from over 70 genes associated with cancer. The results of the liquid biopsy provide doctors with critical information on the type of cancer, the stage, and the specific genomic mutations that could inform treatment decisions.
What Are The Benefits of Guardant Health Inc?
The benefits of the Guardant Health Inc approach are numerous. Firstly, the liquid biopsy is non-invasive, meaning that patients don’t need to undergo invasive procedures like tissue biopsies. Secondly, the test is more accurate than traditional methods, which rely on imaging and tissue samples. Thirdly, the test is faster, providing results in as little as seven days, and is less expensive than traditional methods.
Guardant Health Inc and the Future of Cancer Diagnostics
The Guardant Health Inc approach to cancer diagnostics is a game-changer in the fight against cancer. Its ability to identify ctDNA across a broad spectrum of genes associated with cancer has several implications. Firstly, it can be used to detect cancers early, when treatment is more likely to be effective. Secondly, it can inform personalized treatment decisions, improving patient outcomes. Lastly, the approach has the potential to detect cancer relapses early, providing more opportunities for intervention and improving survival rates.
Conclusion
In conclusion, Guardant Health Inc is revolutionizing cancer diagnosis with its innovative liquid biopsy approach. Its ability to detect ctDNA across a broad spectrum of genes associated with cancer is unmatched by traditional methods. This approach has the potential to transform the way we diagnose, treat, and manage cancer, and improve patient outcomes significantly. With Guardant Health Inc leading the way, the future of cancer diagnostics is bright.
